Literature DB >> 24211469

Structural complementation of the catalytic domain of pseudomonas exotoxin A.

Erin L Boland1, Crystal M Van Dyken1, Rachel M Duckett1, Andrew J McCluskey2, Gregory M K Poon3.   

Abstract

The catalytic moiety of Pseudomonas exotoxin A (domain III or PE3) inhibits protein synthesis by ADP-ribosylation of eukaryotic elongation factor 2. PE3 is widely used as a cytocidal payload in receptor-targeted protein toxin conjugates. We have designed and characterized catalytically inactive fragments of PE3 that are capable of structural complementation. We dissected PE3 at an extended loop and fused each fragment to one subunit of a heterospecific coiled coil. In vitro ADP-ribosylation and protein translation assays demonstrate that the resulting fusions-supplied exogenously as genetic elements or purified protein fragments-had no significant catalytic activity or effect on protein synthesis individually but, in combination, catalyzed the ADP-ribosylation of eukaryotic elongation factor 2 and inhibited protein synthesis. Although complementing PE3 fragments are catalytically less efficient than intact PE3 in cell-free systems, co-expression in live cells transfected with transgenes encoding the toxin fusions inhibits protein synthesis and causes cell death comparably as intact PE3. Complementation of split PE3 offers a direct extension of the immunotoxin approach to generate bispecific agents that may be useful to target complex phenotypes.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADP-ribosylation; ADP-ribosyltransferase; ADPRT; DT; MBP; RRL; SEM; cytotoxicity; diphtheria toxin; eEF2; elongation factor 2; eukaryotic elongation factor 2; exotoxin A; maltose-binding protein; rabbit reticulocyte lysate; standard error of the mean; structural complementation

Mesh:

Substances:

Year:  2013        PMID: 24211469      PMCID: PMC3997303          DOI: 10.1016/j.jmb.2013.11.002

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   6.151


  68 in total

1.  Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments.

Authors:  J N Pelletier; F X Campbell-Valois; S W Michnick
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

2.  Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen.

Authors:  Andrew J McCluskey; Andrew J Olive; Michael N Starnbach; R John Collier
Journal:  Mol Oncol       Date:  2012-12-19       Impact factor: 6.603

3.  Monitoring protein-protein interactions in intact eukaryotic cells by beta-galactosidase complementation.

Authors:  F Rossi; C A Charlton; H M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

Review 4.  Cardiotoxicity of anticancer treatments: what the cardiologist needs to know.

Authors:  Michael S Ewer; Steven M Ewer
Journal:  Nat Rev Cardiol       Date:  2010-10       Impact factor: 32.419

5.  A novel genetic system to detect protein-protein interactions.

Authors:  S Fields; O Song
Journal:  Nature       Date:  1989-07-20       Impact factor: 49.962

Review 6.  Bimolecular fluorescence complementation (BiFC) analysis as a probe of protein interactions in living cells.

Authors:  Tom K Kerppola
Journal:  Annu Rev Biophys       Date:  2008       Impact factor: 12.981

7.  Construction of the plasmid for expression of ETA-EGFP fusion protein under control of the cytomegalovirus promoter and its effects in HeLa cells.

Authors:  Elena M Glinka; Alla S Andryushchenko; Alexander M Sapozhnikov; Olga V Zatsepina
Journal:  Plasmid       Date:  2009-06-13       Impact factor: 3.085

8.  Apoptosis induced by Pseudomonas exotoxin: a sensitive and rapid marker for gene delivery in vivo.

Authors:  P Hafkemeyer; U Brinkmann; M M Gottesman; I Pastan
Journal:  Hum Gene Ther       Date:  1999-04-10       Impact factor: 4.793

9.  Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis.

Authors:  Ashima K Sharma; David FitzGerald
Journal:  Toxicon       Date:  2010-07-24       Impact factor: 3.035

10.  Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses.

Authors:  R J Kreitman; I Pastan
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 13.312

View more
  5 in total

Review 1.  Prodrug applications for targeted cancer therapy.

Authors:  Irene Giang; Erin L Boland; Gregory M K Poon
Journal:  AAPS J       Date:  2014-07-09       Impact factor: 4.009

2.  Intein-mediated cytoplasmic reconstitution of a split toxin enables selective cell ablation in mixed populations and tumor xenografts.

Authors:  Vedud Purde; Elena Kudryashova; David B Heisler; Reena Shakya; Dmitri S Kudryashov
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-24       Impact factor: 11.205

Review 3.  Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents.

Authors:  Akmal M Asrorov; Bahtiyor Muhitdinov; Bin Tu; Sharafitdin Mirzaakhmedov; Huiyuan Wang; Yongzhuo Huang
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

Review 4.  Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective.

Authors:  Mengyu Li; Sen Mei; Yi Yang; Yuelei Shen; Lei Chen
Journal:  Antib Ther       Date:  2022-06-16

5.  Developing a Novel Gene-Delivery Vector System Using the Recombinant Fusion Protein of Pseudomonas Exotoxin A and Hyperthermophilic Archaeal Histone HPhA.

Authors:  Xin Deng; Guoli Zhang; Ling Zhang; Yan Feng; Zehong Li; GuangMou Wu; Yuhuan Yue; Gensong Li; Yu Cao; Ping Zhu
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.